drugset / Trial / NCT06996704
A Clinical Study of AK0610
RandomizedParallel-groupTriple-blindPrevention
Summary
The study consists of two parts: dose escalation and expansion. It includes five cohorts in the dose-escalation phase and two expansion cohorts based on pharmacokinetic data.
Timeline
- Start
- 2024-02-29
- Primary completion
- 2025-06
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK0610 | Unknown | 100 mg | Intramuscular |
| Subject | AK0610 | Unknown | 300 mg | Intramuscular |
| Subject | AK0610 | Unknown | 600 mg | Intramuscular |
| Subject | AK0610 | Unknown | 1000 mg | Intramuscular |
| Subject | AK0610 | Unknown | 3000 mg | Intramuscular |
Indications
No indication recorded.